Literature DB >> 15917245

Amyloid formation modulates the biological activity of a bacterial protein.

Sylvain Bieler1, Lisbell Estrada, Rosalba Lagos, Marcelo Baeza, Joaquín Castilla, Claudio Soto.   

Abstract

The aggregation of proteins into amyloid fibrils is the hallmark feature of a group of late-onset degenerative diseases including Alzheimer, Parkinson, and prion diseases. We report here that microcin E492, a peptide naturally produced by Klebsiella pneumoniae that kills bacteria by forming pores in the cytoplasmic membrane, assembles in vitro into amyloid-like fibrils. The fibrils have the same structural, morphological, tinctorial, and biochemical properties as the aggregates observed in the disease conditions. In addition, we found that amyloid formation also occurs in vivo where it is associated with a loss of toxicity of the protein. The finding that microcin E492 naturally exists both as functional toxic pores and as harmless fibrils suggests that protein aggregation into amyloid fibrils is an evolutionarily conserved property of proteins that can be successfully employed by bacteria to fulfill specific physiological needs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917245     DOI: 10.1074/jbc.M502031200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

1.  Microcin amyloid fibrils A are reservoir of toxic oligomeric species.

Authors:  Mohammad Shahnawaz; Claudio Soto
Journal:  J Biol Chem       Date:  2012-02-15       Impact factor: 5.157

Review 2.  Molecular interactions of amyloid nanofibrils with biological aggregation modifiers: implications for cytotoxicity mechanisms and biomaterial design.

Authors:  Durga Dharmadana; Nicholas P Reynolds; Charlotte E Conn; Céline Valéry
Journal:  Interface Focus       Date:  2017-06-16       Impact factor: 3.906

3.  In vitro polymerization of a functional Escherichia coli amyloid protein.

Authors:  Xuan Wang; Daniel R Smith; Jonathan W Jones; Matthew R Chapman
Journal:  J Biol Chem       Date:  2006-12-12       Impact factor: 5.157

4.  Bactericidal activity of both secreted and nonsecreted microcin E492 requires the mannose permease.

Authors:  Sylvain Bieler; Filo Silva; Claudio Soto; Dominique Belin
Journal:  J Bacteriol       Date:  2006-10       Impact factor: 3.490

5.  The distribution of residues in a polypeptide sequence is a determinant of aggregation optimized by evolution.

Authors:  Elodie Monsellier; Matteo Ramazzotti; Patrizia Polverino de Laureto; Gian-Gaetano Tartaglia; Niccolò Taddei; Angelo Fontana; Michele Vendruscolo; Fabrizio Chiti
Journal:  Biophys J       Date:  2007-08-31       Impact factor: 4.033

6.  Microcin e492 amyloid formation is retarded by posttranslational modification.

Authors:  Andrés Marcoleta; Macarena Marín; Gabriela Mercado; José María Valpuesta; Octavio Monasterio; Rosalba Lagos
Journal:  J Bacteriol       Date:  2013-07-08       Impact factor: 3.490

Review 7.  Polymerizing the fibre between bacteria and host cells: the biogenesis of functional amyloid fibres.

Authors:  Elisabeth Ashman Epstein; Matthew R Chapman
Journal:  Cell Microbiol       Date:  2008-03-26       Impact factor: 3.715

Review 8.  Structural insights into functional and pathological amyloid.

Authors:  Frank Shewmaker; Ryan P McGlinchey; Reed B Wickner
Journal:  J Biol Chem       Date:  2011-03-25       Impact factor: 5.157

Review 9.  Protein folding and aggregation in bacteria.

Authors:  Raimon Sabate; Natalia S de Groot; Salvador Ventura
Journal:  Cell Mol Life Sci       Date:  2010-04-01       Impact factor: 9.261

10.  Loss of metal ions, disulfide reduction and mutations related to familial ALS promote formation of amyloid-like aggregates from superoxide dismutase.

Authors:  Zeynep A Oztug Durer; Jeffrey A Cohlberg; Phong Dinh; Shelby Padua; Krista Ehrenclou; Sean Downes; James K Tan; Yoko Nakano; Christopher J Bowman; Jessica L Hoskins; Chuhee Kwon; Andrew Z Mason; Jorge A Rodriguez; Peter A Doucette; Bryan F Shaw; Joan Selverstone Valentine
Journal:  PLoS One       Date:  2009-03-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.